Intussusception Global Market Report 2024

The intussusception market size has grown strongly in recent years. It will grow from $4.22 billion in 2023 to $4.45 billion in 2024 at a compound annual growth rate (CAGR) of 5.7%. The growth observed in the historical period can be attributed to several factors, including enhanced diagnostic capabilities, increased awareness and education, global expansion of healthcare infrastructure, investments in research and development, and collaborative efforts among healthcare entities.

The intussusception market size is expected to see steady growth in the next few years. It will grow to $5.3 billion in 2028 at a compound annual growth rate (CAGR) of 4.5%. The anticipated growth in the forecast period can be attributed to ongoing medical education initiatives, pediatric vaccination programs, global endeavors in pediatric healthcare, an emphasis on postoperative care, an increasing demand for pediatric gastrointestinal research, and the adoption of telemedicine and remote healthcare access. Major trends expected in the forecast period include advancements in diagnostic imaging, the promotion of minimally invasive treatment approaches, the development of pediatric-specific interventions, research on etiology and risk factors, global epidemiological studies, the implementation of vaccination programs, and the integration of telemedicine for diagnosis and consultation.

The anticipated rise in the incidence of intestinal disorders is poised to drive the growth of the intussusception market in the future. Intestinal disorders encompass various medical conditions affecting the normal functioning of the intestines, which play a crucial role in the digestive system. The increasing occurrence of intestinal disorders, such as inflammatory bowel disease and gastrointestinal cancers, can lead to earlier diagnoses, improved treatment options, and enhanced support for patients with intussusception, ultimately contributing to better health outcomes. For instance, data from the American Cancer Society (ACS) in January 2023 revealed a 3.18% increase in gastrointestinal cancers in the United States, reaching 348,840 cases compared to 338,090 in 2021. Therefore, the rising incidence of intestinal disorders is expected to drive the growth of the intussusception market.

The growth of the intussusception market is further propelled by the increase in healthcare spending. Healthcare spending refers to the total financial resources allocated to the healthcare sector within a specific region, country, or organization. The allocation of financial resources to address medical needs, including conditions such as intussusception, leads to increased spending on medical interventions, diagnostic procedures, and potential surgical treatments, impacting overall healthcare expenditure. For instance, in March 2023, the American Medical Association reported that health spending in the United States increased by 2.7% in 2021, reaching $4.3 trillion or $12,914 per capita. Therefore, the upward trend in healthcare spending is a key driver for the growth of the intussusception market.

The anticipated impact of stringent regulatory policies governing the development and approval of diagnostic tools and treatment options is expected to restrain the growth of the intussusception market. Stringent regulations can pose challenges by imposing rigorous requirements, potentially causing delays in market entry and increasing the overall cost and complexity of introducing new solutions. For example, in July 2022, the World Health Organization (WHO) established the Expert Review Panel for Diagnostics (ERPD) to assist procurers and national programs in evaluating the risks associated with diagnostic tests, especially those that have not undergone stringent regulatory authority assessments. This mechanism aims to ensure the safety and efficacy of diagnostic tools. Consequently, the stringent regulatory policies governing the development and approval of diagnostic tools and treatment options may impede the growth of the intussusception market.

Major companies in the intestinal pseudo-obstruction treatment market are actively involved in developing innovative drug therapies, such as NHE3 inhibitor treatment therapy, to provide reliable services to customers. NHE3 inhibitor treatment therapy involves the inhibition of the Sodium-Proton-Exchanger subtype 3 (NHE3) in the gut. For example, in April 2022, Ardelyx Inc., a US-based biopharmaceutical company, introduced IBSRELA, an NHE3 inhibitor treatment designed for irritable bowel syndrome with constipation (IBS-C) in adults. This therapy has the potential to improve gastrointestinal motility by inhibiting or blocking the activity of the Sodium-Hydrogen Exchanger 3 (NHE3) protein. The approval of IBSRELA was based on two Phase 3 trials involving over 1,200 IBS-C patients. The treatment significantly improved abdominal pain and bowel movements, meeting the primary endpoint. Notably, improvements were observed as early as Week 1 and sustained for 26 weeks in the long-term trial.

In March 2022, Pfizer Inc., a prominent US-based pharmaceutical manufacturing company, acquired Arena Pharmaceuticals, Inc. This acquisition is part of Pfizer's strategic efforts to bolster its portfolio of therapeutic candidates at various stages of development within the field of gastroenterology. Arena Pharmaceuticals, Inc., a US-based clinical-stage company, is actively involved in developing treatments for intestinal diseases, including intussusception (bowel obstruction). The acquisition aligns with Pfizer's commitment to advancing research and development in gastrointestinal therapeutics.

Major companies operating in the intussusception market report are Pfizer Inc., Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Abbott Laboratories, Sanofi S.A., GlaxoSmithKline PLC, Stryker Corporation, Boston Scientific Corporation, Biogen Inc., Olympus Corporation, GE HealthCare Technologies Inc., Steris PLC, Cook Medical LLC, Shimadzu Corporation, Carestream Health, CONMED Corporation, Janssen Pharmaceuticals Inc., EndoChoice Holdings Inc., Fujifilm Healthcare Solutions, Basilea Pharmaceutica Ltd., Richard Wolf GmbH, Karl Storz SE And Co. KG, Eizoflex Co. Ltd., Arena Pharmaceuticals Inc.

North America was the largest region in the intussusception market in 2023. The regions covered in the intussusception market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the intussusception market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Intussusception is a medical condition wherein one part of the intestine slides into an adjacent section, causing a blockage in the flow of food, fluids, and gas through the affected portion. This condition manifests with symptoms such as severe abdominal pain, vomiting, and bloody stools. Diagnosis of intussusception typically relies on symptoms, physical examination, and imaging tests.

There are two main types of intussusception are idiopathic intussusception and secondary intussusception. Idiopathic intussusception involves the telescoping or invagination of one part of the intestine into another, resulting in a blockage or obstruction that can often be treated non-surgically through procedures such as pneumatic or hydrostatic reduction. Treatment methods include enema reduction, surgery, and others, with diagnostic approaches such as barium enema, ultrasound, and X-ray. These services are generally provided by hospitals, clinics, and other medical facilities.

The intussusception market research report is one of a series of new reports that provides intussusception market statistics, including intussusception industry global market size, regional shares, competitors with an intussusception market share, detailed intussusception market segments, market trends and opportunities, and any further data you may need to thrive in the intussusception industry. This intussusception market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The intussusception market consists of revenues earned by entities that provide diagnostic services such as clinical examination, magnetic resonance imaging, exploratory laparoscopy, or laparotomy that help in diagnosing and managing intussusception as a medical condition. The market value includes the value of related goods sold by the service provider or included within the service offering. The intussusception market also includes sales of drugs such as acetaminophen with codeine and ibuprofen. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.